We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-11.17%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$775M
AUM Growth
-$224M
Cap. Flow
-$90.9M
Cap. Flow %
-11.73%
Top 10 Hldgs %
46.3%
Holding
85
New
17
Increased
18
Reduced
18
Closed
20

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$27M
2
OSUR icon
OraSure Technologies
OSUR
+$24.4M
3
ILMN icon
Illumina
ILMN
+$21.6M
4
ACLX
Arcellx
ACLX
+$16.5M
5
HOLX
Hologic
HOLX
+$16.2M

Top Sells

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$59.5M
2
AZN icon
AstraZeneca
AZN
+$21.9M
3
CCCC icon
C4 Therapeutics
CCCC
+$9.58M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$7.53M
5
SNN icon
Smith & Nephew
SNN
+$6.99M

Sector Composition

Rank Sector Weight
1 Healthcare 80.09%
2 Financials 0.5%
3 Consumer Staples 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$127M 16.33%
+1,408,100
New +$130M
UTHR icon
2
United Therapeutics
UTHR
$26.3B
$54.9M 7.08%
305,850
+141,550
+86% +$27M
EPIX
3
DELISTED
ESSA Pharma
EPIX
$26.1M 3.37%
4,223,799
+698,342
+20% +$6.14M
SRDX
4
DELISTED
Surmodics
SRDX
$25.3M 3.27%
558,440
+25,683
+5% +$1.12M
FOCL
5
EDAP TMS S.A.
FOCL
$226M
$22.8M 2.94%
3,148,609
– –
ANGO icon
6
AngioDynamics
ANGO
$562M
$22.1M 2.85%
1,026,450
+511,000
+99% +$11.6M
ILMN icon
7
Illumina
ILMN
$29.4B
$21.8M 2.81%
+64,044
New +$21.6M
OSUR icon
8
OraSure Technologies
OSUR
$273M
$20.7M 2.67%
+3,055,193
New +$24.4M
ORGO icon
9
Organogenesis Holdings
ORGO
$308M
$19.4M 2.5%
2,540,167
+541,080
+27% +$4.19M
IRMD icon
10
iRadimed
IRMD
$1.21B
$19.3M 2.49%
430,051
-19,979
-4% -$924K
KRYS icon
11
Krystal Biotech
KRYS
$9.88B
$19.3M 2.48%
289,337
+60,900
+27% +$3.8M
NPCE icon
12
Neuropace
NPCE
$505M
$19.1M 2.46%
2,324,003
+15,000
+0.6% +$129K
THER
13
DELISTED
THERATECHNOLOGIES INC COM
THER
$18.8M 2.43%
7,692,082
– –
DICE
14
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$18.8M 2.43%
983,994
+173,054
+21% +$3.09M
APEN
15
DELISTED
Apollo Endosurgery, Inc.
APEN
$17.5M 2.26%
2,893,100
+598,000
+26% +$3.64M
HOLX
16
DELISTED
Hologic
HOLX
$17.3M 2.24%
+225,600
New +$16.2M
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$16.2M 2.09%
964,476
-103,900
-10% -$1.54M
EOLS icon
18
Evolus
EOLS
$394M
$15.4M 1.98%
1,368,389
+109,500
+9% +$933K
ENTA icon
19
Enanta Pharmaceuticals
ENTA
$372M
$14.4M 1.86%
202,485
-115,790
-36% -$7.53M
NRIX icon
20
Nurix Therapeutics
NRIX
$2.43B
$14.2M 1.83%
1,011,638
+268,400
+36% +$4.76M
ACLX
21
DELISTED
Arcellx
ACLX
$13.9M 1.79%
+989,739
New +$16.5M
KYNB
22
Kyntra Bio
KYNB
$28.5M
$12.8M 1.65%
42,574
-19,446
-31% -$6.78M
BCAB icon
23
BioAtla
BCAB
$5.59M
$12.6M 1.62%
50,308
– –
PVLA
24
Palvella Therapeutics
PVLA
$1.98B
$12.5M 1.62%
51,686
+43,093
+501% +$11.3M
INSP icon
25
Inspire Medical Systems
INSP
$1.42B
$12.3M 1.59%
47,900
+20,450
+74% +$4.67M
1
2 3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Soleus Capital Management held 85 positions worth $775M, down 22% from $999M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Soleus Capital Management withdrew a net $90.9M in Q1 2022, closing 20 positions and reducing 18 holdings. Its most notable exit was Bioventus, an estimated $6.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 71% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in OraSure Technologies worth $20.7M.

  • Soleus Capital Management's largest Q1 2022 buy was OraSure Technologies: 3,055,193 shares worth $20.7M.
  • Soleus Capital Management added most to United Therapeutics in Q1 2022, an estimated $27M increase.
  • Soleus Capital Management's biggest Q1 2022 reduction was Lantheus, cutting an estimated $59.5M.
  • Soleus Capital Management fully exited Bioventus in Q1 2022, selling an estimated $6.21M.
  • Soleus Capital Management's ten largest holdings make up 46% of its $775M portfolio in Q1 2022.
  • Soleus Capital Management opened 17 new positions and closed 20 in Q1 2022.
  • Soleus Capital Management's portfolio value fell 22% quarter-over-quarter to $775M.

Based on Soleus Capital Management's 13F filing for Q1 2022, filed 16 May 2022.